Nuvation Bio Inc., a global oncology company, has released a corporate presentation highlighting its recent achievements and ongoing projects in cancer treatment. The presentation details the approval of IBTROZITM (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1+ non-small cell lung cancer (NSCLC) in both the U.S. and China. Additionally, Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering pivotal studies for diffuse IDH1-mutant glioma. The company is also advancing NUV-1511, a clinical-stage drug-drug conjugate, in a Phase 1/2 study and has completed Phase 1 and Phase 1b studies for NUV-868, a BD2-selective BET inhibitor. With a robust cash balance and potential additional funding, Nuvation Bio is poised for further developments in its oncology programs. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。